First Participant Dosed in Europe as Cognition Therapeutics Expand Phase 2 Alzheimer's Disease Clinical Trial of Oral CT1812
15 déc. 2022 08h00 HE
|
Cognition Therapeutics, Inc.
PURCHASE, N.Y., Dec. 15, 2022 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (Nasdaq: CGTX) (the “Company” or “Cognition”), announced that the Phase 2 SHINE clinical trial of CT1812, an...
Cognition Therapeutics Presents Scientific Rationale, Clinical Biomarker and Preclinical Data supporting a Phase 2 Clinical Trial with CT1812 in Geographic Atrophy Secondary to Dry AMD
01 déc. 2022 07h30 HE
|
Cognition Therapeutics, Inc.
PURCHASE, N.Y., Dec. 01, 2022 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., (Nasdaq: CGTX), (the “Company” or “Cognition”) today announced that the scientific rationale, supporting...
Cognition Therapeutics Highlights Phase 2 SHIMMER Study of CT1812 in Dementia with Lewy Bodies in Presentation at CTAD
28 nov. 2022 08h00 HE
|
Cognition Therapeutics, Inc.
PURCHASE, N.Y., Nov. 28, 2022 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., (Nasdaq: CGTX), (the “Company” or “Cognition”), today announced that the rationale and design of the Company’s ongoing...
Cognition Therapeutics Launches Neuroscience Thought Leader Conversations Podcast/Webinar Series
21 nov. 2022 08h00 HE
|
Cognition Therapeutics, Inc.
PURCHASE, N.Y., Nov. 21, 2022 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., (Nasdaq: CGTX), (the “Company” or “Cognition”) has introduced a new podcast/webinar series named “Conversations,” that...
Cognition Therapeutics Announces Closing of Public Offering
15 nov. 2022 12h55 HE
|
Cognition Therapeutics, Inc.
PURCHASE, N.Y., Nov. 15, 2022 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., (Nasdaq: CGTX), (the “Company” or “Cognition”) today announced the closing of its previously announced underwritten...
Cognition Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business Update
14 nov. 2022 08h00 HE
|
Cognition Therapeutics, Inc.
- SHINE Alzheimer’s Trial Expands to European Sites - - SEQUEL Alzheimer’s Trial Awarded Additional NIA Grant to Complete - - Over 50% of SHIMMER Dementia with Lewy Bodies Study Sites Active - ...
Cognition Therapeutics Announces Pricing of Public Offering
10 nov. 2022 08h00 HE
|
Cognition Therapeutics, Inc.
PURCHASE, N.Y., Nov. 10, 2022 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., (Nasdaq: CGTX), (the Company” or “Cognition”) announced today the pricing of the public offering of 5,000,000 shares...
Cognition Therapeutics is Recruiting for Lewy Body Dementia Phase 2 SHIMMER Trial in Seventeen Research Sites Across the U.S.
12 oct. 2022 08h00 HE
|
Cognition Therapeutics, Inc.
PURCHASE, N.Y., Oct. 12, 2022 (GLOBE NEWSWIRE) -- Lewy Body Dementia (LBD) patients are actively being recruited by Cognition Therapeutics, Inc. (Nasdaq: CGTX) and its clinical partners for the...
Cognition Therapeutics Appoints CNS Drug Development Expert to VP Clinical Development
11 oct. 2022 08h00 HE
|
Cognition Therapeutics, Inc.
PURCHASE, N.Y., Oct. 11, 2022 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (Nasdaq: CGTX), announced the appointment of Paul J. Tiseo, Ph.D. to the newly created role of vice president of...
Cognition Therapeutics to Participate in the 2022 Cantor Fitzgerald Neurology & Psychiatry Conference
29 sept. 2022 07h30 HE
|
Cognition Therapeutics, Inc.
PURCHASE, N.Y., Sept. 29, 2022 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (Nasdaq: CGTX) (the “Company” or “Cognition”), a clinical-stage biopharmaceutical company engaged in the discovery and...